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A comparison of Percutaneous femoral
access in Endovascular Repair versus Open
femoral access (PiERO): study protocol for a
randomized controlled trial
Bastiaan P. Vierhout1*, Ben R. Saleem2, Alewijn Ott3, Jan Maarten van Dijl4, Ties D. van Andringa de Kempenaer5,
Maurice E. N. Pierie6, Jan T. Bottema7 and Clark J. Zeebregts2
Abstract
Background: Access for endovascular repair of abdominal aortic aneurysms (EVAR) is obtained through surgical
cutdown or percutaneously. The only devices suitable for percutaneous closure of the 20 French arteriotomies of
the common femoral artery (CFA) are the Prostar™ and Proglide™ devices (Abbott Vascular). Positive effects of these
devices seem to consist of a lower infection rate, and shorter operation time and hospital stay. This conclusion was
published in previous reports comparing techniques in patients in two different groups (cohort or randomized).
Access techniques were never compared in one and the same patient; this research simplifies comparison because
patient characteristics will be similar in both groups.
Methods/Design: Percutaneous access of the CFA is compared to surgical cutdown in a single patient; in EVAR surgery,
access is necessary in both groins in each patient. Randomization is performed on the introduction site of the larger
main device of the endoprosthesis. The contralateral device of the endoprosthesis is smaller. When we use this type of
randomization, both groups will contain a similar number of main and contralateral devices. Preoperative nose cultures
and perineal cultures are obtained, to compare colonization with postoperative wound cultures (in case of a surgical site
infection). Furthermore, patient comfort will be considered, using VAS-scores (Visual analog scale). Punch
biopsies of the groin will be harvested to retrospectively compare skin of patients who suffered a surgical site
infection (SSI) to patients who did not have an SSI.
Discussion: The PiERO trial is a multicenter randomized controlled clinical trial designed to show the
consequences of using percutaneous access in EVAR surgery and focuses on the occurrence of surgical site
infections.
Trial registration: NTR4257 10 November 2013, NL44578.042.13.
Background
Percutaneous endovascular abdominal aortic aneurysm
repair (pEVAR) has been stated to be safe and feasible [1],
even though several publications report a substantial
number of complications [2–4]. With evolving experience,
various risk factors have been identified, including obesity,
groin scarring, common femoral artery (CFA) morphology
and tortuous iliac arteries [1, 5].
Many current devices successfully close percutaneous
punctures of the CFA up to 8 Fr.: such as the Angio-
Seal™ (St. Jude Medical, Minnetonka, MN, USA), Mynx™
(AccessClosure, Mountain View, CA, USA), and the
Starclose™ device (Abbott Vascular, Redwood City, CA,
USA). The Prostar XL™ device (Abbott Vascular) has
been used in femoral arteries, after sheaths of 18 to 24
Fr., with high rates of procedural success [1]. Wound
infections appear to be absent [3, 6, 7] or few (0.2 %) [8].
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In contrast, open femoral access has wound infection
rates varying from 6.4 % [9] to 7.3 % [7]. Also, a longer
surgery and hospital stay have been reported [10–12]. In
percutaneous access, secondary interventions were more
commonly seen, compared to surgical cutdown [10, 11].
Still, in suitable patients, this seems to be the only device
capable of closing a 20 Fr. percutaneous arterial access
site.
Although research has been performed, comparing both
techniques, a comparison of both techniques in one
patient has never been performed prior to now. Risk fac-
tors (obesity, CFA morphology and tortuosity of the iliac
arteries) will be equally divided in this study design.
Therefore, postoperative complications will mainly de-
pend on the technique used and on the diameter of the
device implanted. Also, each patient will be able to com-




In the current study, percutaneous femoral access is com-
pared to open femoral access. Bilateral femoral access is
required in each patient treated with a bifurcated EVAR.
Therefore, each patient can serve as his/her own control.
Randomization is performed for the caliber of the endo-
vascular device (main device versus contralateral exten-
sion) that is introduced within the aorta.
The PiERO trial is designed as a randomized, controlled,
nonblinded, multicenter superiority trial with two parallel
groups and a primary endpoint of wound infection during
the 30 days after surgery. Simple randomization will be
performed concerning the diameter of the device compo-
nent introduced in the artery, with a 1:1 allocation.
Sample size calculation
The assumption has been made that a pEVAR is less
likely to cause a surgical site infection (SSI) than an
EVAR with surgical cutdown to the femoral artery. We
estimated the number of patients needed in a superiority
trial with an effect size of 90 % and a margin of 10
(alpha 5 %, power 80 %). Assuming an SSI incidence of
6.8 % (Table 1) in an open surgical femoral cutdown and
of 0.1 % in pEVAR, where p1 = 0.068 and p2 = 0.001 and
using the equation n = 8 × (p1(1 − p1) + p2(1 − p2))/(p1 −
p2)2 [13], 120 patients are required to reach sufficient
evidence and avoid a type 2 error (including a fall-out
percentage of 5 %).
Setting
The trial is a multicenter trial, including one academic
hospital and four general hospitals in the northern part of
the Netherlands. In each center, all vascular surgeons
perform surgeries for this study (Table 2). Participating
hospitals are outlined on www.pierotrial.nl. In participat-
ing centers, each surgeon or interventionalist performing
the procedure must have had the experience of 20
Prostar™procedures or 10 Proglide™ procedures prior
to including patients in the PiERO trial, to prevent a
performance bias. The Proglide™ procedure is a pro-
cedure easier to master. A minimum experience of 20
surgical cut downs to the common femoral artery
(CFA) is also required. All punctures of the CFA
should be performed with ultrasound guidance.
Primary endpoints
The primary endpoints include the number of SSI’s in
the groin within 30 days postoperatively and at final
evaluation 1 year after the operation. Wounds will be
evaluated by means of the Southampton Wound Assess-
ment score [14]. This score lowers the variability in
wound assessment by various researchers. When an SSI
is diagnosed, both clinically and through the SWA score
(Grade III or more), a wound culture should confirm the
diagnosis, as described in the CDC definition (Centers
for Disease Control and Prevention) [15].
Secondary endpoints
Wound complications in both groups are assessed dur-
ing the first 30 days postoperatively. Close attention will
be paid to hematoma, femoral neuropathy, dehiscence,
fluid discharge, stenotic/occlusive complications in the
CFA and signs of infection.
When a Staphylococcus aureus SSI occurs (as the
major contributor to all in the groin), preoperative
Table 1 Wound complication rates mentioned in various studies
Studies Surgical cutdown Percutaneous access Number of patients P value Research type
Johanning (2001) [8] nm 0.2 489 - retrospective
Nehler (2001) [3] nm 0 189 - systematic review
Eisenack (2009) [6] nm 0 500 - prospective
Zhong (2011) [7] 7.3 0 236 <0.01 retrospective
RIVM (2014) 6.4 nm 329 - retrospective
Total: 6.8 0.1 1743
nm not mentioned
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isolates will be compared to postoperative SSI involved
strains.
All patients will score their wound comfort or pain in
a validated VAS score 1 day, and 2 weeks after surgery.
Outcomes for open femoral versus percutaneous access
will be compared.
Percutaneous access of the CFA is expected to inflict
less surgical site infections in the groin compared to
open surgical cutdown of the CFA. A lower incidence of
infections and localized postoperative problems is ex-
pected to offset the additional costs of the percutaneous
device. Still, the reduction in complaints needs to be
quantified.
Follow-up will be performed until 1 year after the
operation, according to the definition of a surgical
site infection: “if implant (the endoprosthesis) is in
place and the infection appears to be related to the
operation” [15].
Recent studies suggest that certain patients may be
colonized by multiple different S. aureus clones [16].
Also, these bacteria may hide intracellularly [17]. In case
of a SSI, we hope to identify the initial localization of
the causative microorganism. Therefore, preoperative
cultures and punch biopsies will be used, respectively, to
study the clonality of isolates by genotyping and to
identify intracellular bacteria by fluorescence in situ
hybridization (FISH) and fluorescence microscopy [18].
Ethical considerations
Patients who meet the entry criteria will be fully informed
about the trial and provided with a patient information
and consent form. Patients willing to participate in the
study will be included after signing the informed consent
form. This study is being conducted in accordance with
the principles of the Declaration of Helsinki and Good
Clinical Practice guidelines. The protocol, site-specific in-
formed consent forms, participant education and recruit-
ment materials, and other requested documents were
reviewed and approved by the Medical Ethics committee
of Groningen (CMO 2013-365) and the local institutional
board of each participating center (Table 2).
Safety and quality control
Adverse events (AE) are defined as any undesirable ex-
perience occurring to a participant during the study,
whether or not considered related to the investigational
device. This definition includes events occurring during
the hospital stay and up to 30 days of follow-up. Under-
lying disease that was present at the time of enrollment
is not reported as an AE, but any increase in the severity
of the underlying disease will be reported as an AE. All
AEs will be monitored from the time of enrollment
through the 30-day follow-up. AE’s will be recorded on
the case record forms (CRFs). A description of the event,
including the start date, end date, action taken and the
outcome will be reported.
A severe adverse event (SAE) is any event leading to
death, major amputation, prolonged hospitalization or
renewed hospitalization due to complications and will be
communicated to the Medical Ethical committee through
“Toetsingonline.”
Inclusion criteria
In order to be eligible to participate in this study, a sub-
ject must meet all of the following criteria:
1. More than 18 years of age.
2. Informed consent.
Table 2 Participating centers, local judging committees and number of surgeons
Participating center Local medical ethical committee Number of surgeons
Isala Hospital METC Isala four vascular surgeons
Dr. van Deenweg 1 to 11
Zwolle




Scheper Hospital Emmen METc Scheper Hospital two vascular surgeons
Boermarkeweg 60
Emmen
University Medical Center of Groningen METc UMCG five vascular surgeons
Wilhelmina Hospital Assen Board of Governance two vascular surgeons
Europaweg-Zuid 1
Assen
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3. Physically and mentally capable of giving consent for
participation and data storage.
4. diagnosed with an aneurysm of the abdominal aorta
with a diameter of at least 55 mm (or growth of
5 mm or more in 6 months) suitable for bifurcated
endovascular repair through two femoral access
sites, without additional access needed.
Exclusion criteria
Exclusion criteria are indicated as follows:
1. Patients with severe atherosclerosis at the access site
(more than 50 % of the circumference of the common
femoral artery).
2. Patients with previous common femoral artery
surgery.
3. Patients with a documented infection at the time of
operation.
4. Patients treated with an aorto-monoiliacal device
implanted, followed by a femoro-femoral crossover.
5. Patients with an aneurysm necessitating more than
two accesses (brachial or carotid) for repair.
Recruitment
Patients more than 18 years of age and presenting at the
outpatient clinic of participating hospitals, with an indica-
tion for bifurcated EVAR will be asked to participate.
Patients will be informed about the purpose, and interven-
tion of the study, its duration and the risks. Consent will
be obtained with explanation and a signature on the In-
formed Consent Form. Patients have 1 week to consider
their decision.
Withdrawal from the study is possible at any time for
any reason and is without further consequences.
Randomization
Randomization will be performed prior to operation.
The operating physician or his/her assistant must draw a
blinded envelop to allocate the patient to one of the two
groups.
In the first group (group A), surgical access is achieved
for the main body of the endoprosthesis. In the second
group (group B), the Prostar XL™/Proglide™ device gives
passage to the main device.
The allocation will be noted at the case report form
(CRF) present in the envelope, which also contains a cir-
cular blade of 3 mm diameter, and 3 culture mediums
(Thioglycollate medium USP, Mediaproducts, Groningen,
Germany). Two cultures are taken after completion of the
preoperative checklist and after administration of prophy-
lactic antibiotics (1 g cefazolin, intravenously 15 to 60 min
before surgery): one nose culture and one perineal culture
is performed with a swab, rotated at the nasal and perineal
site. The punch biopsy is collected from the right groin
after disinfection, a circular blade of 3 mm is rotated and
2 skin biopsies are harvested. One punch biopsy is stored
in formaldehyde; the second punch biopsy is stored in the
third culture medium.
The culture media and formaldehyde storages have
been coded in advance by the investigator, who prepared
the content of the blinded envelop, and these samples
will be sent to the laboratory of CERTE in an enclosed
addressed envelope.
Blinding
The operating team cannot be blinded for the allocation.
Medical staff responsible for control visits and wound
evaluation will be blinded for the passage of the main
device or the contralateral leg. The scar of the Prostar
XL™/Proglide™ device will, however, be smaller. This is
an investigator-blinded study.
Emergency unblinding
To maintain the overall quality and legitimacy of the
clinical trial, code breaks should occur only in exceptional
circumstances when knowledge of the actual treatment is
absolutely essential for further management of the patient.
If unblinding is deemed necessary, the investigator should
use the system for emergency unblinding through contact-
ing the supervising investigator in writing. The objective
database manager, who supervises the codes, is not
allowed to give access to the coded patients, unless the




Participants are enrolled in the PiERO trial during their
preoperative evaluation. Postoperative assessment is per-
formed during the regular outpatient follow up.
Concomitant care
In case of an SSI, the wound must be opened, cul-
tured and rinsed with clean water, as considered
appropriate according to the treating physician.
When infection persists or escalates, oral or intraven-
ous antibiotics are administered. If a second oper-
ation is necessary to restrain an infection, this will
be registered as an AE.
This trial has no prohibited concomitant medication.
Follow-up
Wound control is performed at 1 day, 2 weeks and
6 weeks after operation. Final evaluation will take place
at 1 year after the procedure. This evaluation will be
carried out for infection of the endoprosthesis,
according to the definition [15]. The wound evalu-
ation is carried out using the Southampton Wound
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Assessment score. Wound complications emerging in
between measuring points (1 day, 2 weeks and 6 weeks)
will also be recorded.
Three VAS scores (Visual Analog Scale) will be
obtained before the operation, 1 day after the operation,
and 2 weeks after the operation.
Scores are registered in the CRF (case report form)
and collected by the objective database manager
(Table 3).
Data management
All forms, diskettes and tapes related to study data will
be kept by the database manager. Access to the study
data will be restricted. Values will be stored in an Excel
sheet. Each additional value added to the database
will be stored in consecutively numbered Excel doc-
uments, in a security-coded computer. A complete
back up of the primary DCC database will be per-
formed weekly and will be stored in locked files
(data cannot be altered).
Statistical analyses
Primary study parameter(s)
The occurrence of SSIs in both groups will be compared
with a McNemar’s test and proportional hazards regres-
sion. Only two measuring points will be defined, but
wound complications are expected to emerge also
between these measuring points. A Kaplan Meier curve
may be used to log incidences according to time. Both
groups will be compared using the log rank test.
Secondary study parameter(s)
The number of wound complications in both groups will
be compared as mentioned previously.
Patient characteristics will be controlled by multivariate
analysis with respect to the duration of operation, left/
right differences, preoperative bacterial colonization of the
nose and the perineum, diabetes mellitus, body mass
index, medication, smoking habits and device failure.
Although identical groups are examined, we will be able
to identify outliers.
Correlations between factors will be estimated using
the Pearson correlation coefficient. Proportions of
categorical variables are compared using Chi square and
Fisher Exact tests, and means of continuous variables
are compared using t tests.
The analysis of the primary endpoint (surgical site infec-
tion) will be based on an intention-to-treat principle by
proportional hazards regression (visualized by Kaplan-
Meier survival curves). Intention-to-treat implies that
open access because of failed percutaneous access is not
excluded from analysis but remains in the percutaneous
group. Reasons why percutaneous access may not be suc-
cessful are inability to obtain access to the arterial lumen
with a needle, rupture of the threads of the Prostar XL™
device/2 Proglide™ devices, necessitating open repair and
persistent bleeding despite successful use of the Prostar
XL™ device/2 Proglide™ devices. The survival analysis
is not affected by patient withdrawals (as they will be
censored) provided that dropping out is unrelated to
prognosis (Table 4). Other outcomes, such as VAS
scores 2 weeks post-randomization, may be missing
for patients who withdraw from the trial. We will
actively seek out reasons for withdrawal and compare
the reasons qualitatively.
Publication of data
The scientific integrity of the project requires that the
data from all sites be analyzed study-wide and
reported as such. Thus, an individual center is not
expected to report the data collected from its center
alone. All presentations and publications are expected
to protect the integrity of the major objectives of the
study.
Recommendations will be given by Abbott, and Abbott
will be granted the nonexclusive right to use any publica-
tion or presentation resulting from the research.
Publications will be prepared under the responsibil-
ity of the principle investigator and the contributions
of all authors will be specified. A copy of such publi-
cation will be provided to Abbott for its review and
comment. The principle investigator will give due
consideration to any comments made by Abbott.
Changes will be incorporated only when Abbott will
require protection of Abbott’s proprietary rights and
interests. This will not interfere with the ethical responsi-
bility to disseminate the trial results in an unbiased and
timely manner; consequently, Abbott cannot prohibit
publication.
Discussion
Comparison of the incidence of SSIs in one patient may
answer (an important part of) the question whether
Table 3 Timeline for participants
Before operation 1 day after surgery 2 weeks after surgery 6 weeks after surgery 1 year after surgery
VAS score X X X
Wound assessment X X X X
VAS, visual analog scale
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percutaneous closure devices deserve a role in the pre-
vention of SSIs after EVAR. The cost of an SSI is es-
timated to be between US $10.000, and $20.000 per
infection [19]. In pEVAR, a trend was noticed to
reduce procedure and hospitalization times [10–12, 20].
The aim of this study is to contribute to the rationale
of using percutaneous devices for femoral access in
EVAR.
Analysis will be performed on an intention-to-treat
basis. When a percutaneous access, for some reason, is
not successful, open access will be obtained. Reasons
why percutaneous access may not be successful are
described in the Statistical Analysis section.
For all participants, cultures of the nose and the
perineum will be taken preoperatively. In addition,
two punch biopsies from the right groin will be
obtained to evaluate the presence of microorganisms
in deeper layers of the skin or intracellularly (by
culture/molecular methods and PA research). The
intention is to compare cultures and SSIs as it be-
comes more apparent that differences in hostility be-
tween bacterial species and/or clones exists [16, 17].
Therefore, the assumption was made, that a SSI does
not only develop due to flaws in sterility [21], but
also because some bacteria might be able to conceal
themselves better in or on their host, than other bac-
teria. We know that bacteria can hide intracellularly
[17, 22], and take over resistance genes from each
other. Therefore, it might be interesting to compare
S. aureus strains not causing SSIs, to those that do
cause an SSI.
In conclusion, the PiERO trial is a multicenter ran-
domized controlled clinical trial designed to show
the consequences of using percutaneous access in
EVAR surgery, when considering surgical site infec-
tions. In addition, patient comfort, estimated hospital
stay and other wound complications are taken under
consideration.
Trial status
Patients have been included as follows in the various
participating centers:
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